Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RpexBio COVID-19 variant-targeting mRNA vaccine
- Development stage
- Preclinical
- Lead developer
- RpexBio
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
RpexBio's COVID-19 variant-targeting messenger RNA vaccine is an investigational prophylactic mRNA vaccine developed by Suzhou RpexBio Co., Ltd. The vaccine is specifically designed to target SARS-CoV-2 Omicron variants using the company's proprietary mRNA technology platform. It works by delivering synthetic messenger RNA that encodes the viral spike protein of specific Omicron lineages. Upon administration, host cells translate this mRNA into the spike protein antigen, which subsequently triggers a comprehensive immune response, including the production of neutralizing antibodies and the activation of T-cells. This candidate is currently in the IND-enabling phase of development, with regulatory filings for clinical trials anticipated to begin in 2025.
- Other names
- COVID-19 variant-targeting messenger RNA vaccine (RpexBio)RpexBio mRNA COVID-19 vaccineRpexBio Omicron variant mRNA vaccine
02
Targets
SARS-CoV-2 spikelet-7f-5p (microRNA let-7f-5p)
Beyond the preview
Go deeper on RpexBio COVID-19 variant-targeting mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RpexBio COVID-19 variant-targeting mRNA vaccine.